Bristol-Myers' clazakizumab looks to be comparable to Humira in RA

|About: Bristol-Myers Squibb Company (BMY)|By:, SA News Editor

Bristol-Myers Squibb (BMY) says clazakizumab appears to be comparable to Humira (ABBV) in reducing the symptoms of RA when taken in combination with methotrexate.

Trial results show 78% of patients taking clazakizumab with methotrexate saw their symptoms reduced by 20% versus 76% of patients taking Humira and methotrexate.

"We’re very excited about the results here, and we’re mapping out the next phases of the development plan,” BMY's Pushkal Garg tells Bloomberg.